Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial (Q42497114)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

1 reference

based on heuristic

inferred from title

Federico Piacentini

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Maria Vittoria Dieci

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Pierfranco Conte

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Valentina Guarneri

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

A Prat

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

E Tagliafico

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

L Paré

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

G Ficarra

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

G Bisagni

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

D G Generali

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

publication date

2 August 2016

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

27

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1867-1873

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Supervised risk predictor of breast cancer based on intrinsic subtypes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Clinical implications of the intrinsic molecular subtypes of breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Inflammatory cell infiltration of tumors: Jekyll or Hyde

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

The immune system and response to HER2-targeted treatment in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW262

21 January 2018

Identifiers

10.1093/ANNONC/MDW262

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27484801%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42497114&oldid=1959879989"